Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.

Literature DB >> 34152031

Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 34152031 PMCID： PMC8262304 DOI： 10.1002/onco.13866

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

Keyword Cloud
References

× No keyword cloud information.

2 in total

1. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Authors: Dennis J Slamon; Patrick Neven; Stephen Chia; Peter A Fasching; Michelino De Laurentiis; Seock-Ah Im; Katarina Petrakova; Giulia Val Bianchi; Francisco J Esteva; Miguel Martín; Arnd Nusch; Gabe S Sonke; Luis De la Cruz-Merino; J Thaddeus Beck; Xavier Pivot; Gena Vidam; Yingbo Wang; Karen Rodriguez Lorenc; Michelle Miller; Tetiana Taran; Guy Jerusalem
Journal: J Clin Oncol Date: 2018-06-03 Impact factor: 44.544

2. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

Authors: Dennis J Slamon; Patrick Neven; Stephen Chia; Peter A Fasching; Michelino De Laurentiis; Seock-Ah Im; Katarina Petrakova; Giulia V Bianchi; Francisco J Esteva; Miguel Martín; Arnd Nusch; Gabe S Sonke; Luis De la Cruz-Merino; J Thaddeus Beck; Xavier Pivot; Manu Sondhi; Yingbo Wang; Arunava Chakravartty; Karen Rodriguez-Lorenc; Tetiana Taran; Guy Jerusalem
Journal: N Engl J Med Date: 2019-12-11 Impact factor: 91.245

2 in total